The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
Acute Leukemia
DRUG: Bevacizumab
Negative conversion rate of evaluable residual lesions (MRD), 1 year
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults